Evidence map›Paper›PMID 27942580›Full record

ArticleNPJ breast cancer2016

Genetic variation in the insulin, insulin-like growth factor, growth hormone, and leptin pathways in relation to breast cancer in African-American women: the AMBER consortium.

Edward A Ruiz-Narváez, Kathryn L Lunetta, Chi-Chen Hong, Stephen Haddad, Song Yao, Ting-Yuan David Cheng, Jeannette T Bensen, Elisa V Bandera, Christopher A Haiman, Melissa A Troester and 3 more

Open access · goldAbstract read
In one paragraph

Article in NPJ breast cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Dancing from bottoms up - Roles of the POZ-ZF transcription factor Kaiso in Cancer.Biochimica et biophysica acta. Reviews on cancer · 2019
    Review
  8. Article
  9. Common Genetic Variation and Breast Cancer Risk-Past, Present, and Future.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Edward A Ruiz-NarváezSlone Epidemiology Center at Boston University, Boston, MA, USA.
Kathryn L LunettaDepartment of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
Chi-Chen HongDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
Stephen HaddadSlone Epidemiology Center at Boston University, Boston, MA, USA.
Song YaoDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
Ting-Yuan David ChengDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
Jeannette T BensenDepartment of Epidemiology, Gillings School of Global Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Elisa V BanderaRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Christopher A HaimanDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Melissa A TroesterDepartment of Epidemiology, Gillings School of Global Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Christine B AmbrosoneDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
Lynn RosenbergSlone Epidemiology Center at Boston University, Boston, MA, USA.
Julie R PalmerSlone Epidemiology Center at Boston University, Boston, MA, USA.
Boston University · USRoswell Park Comprehensive Cancer Center · USUniversity of North Carolina at Chapel Hill · USRutgers, The State University of New Jersey · USUniversity of Southern California · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Tissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KATHERINE A. HOADLEY · 1992 to 2026
$59.3M
GENETIC SUSCEPTIBILITY TO CANCER IN MULTIETHNIC COHORTSR01CA063464 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 2001 to 2005
$23.2M
FOLLOW-UP STUDY FOR CAUSES OF ILLNESS IN BLACK WOMENR01CA058420 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ROSENBERG, LYNN · 1999 to 2013
$20.7M
Reproduction, Lactation and Hormonal Factors in Breast Cancer SubtypesP01CA151135 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI AMBROSONE, CHRISTINE B., OLSHAN, ANDREW · 2011 to 2017
$18.1M
A Follow-up Study for Causes of Cancer in Black WomenUM1CA164974 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ROSENBERG, LYNN · 2012 to 2017
$13.7M
Understanding Ethnic Differences in Cancer: The Multiethnic Cohort StudyUM1CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HENDERSON, BRIAN E, LE MARCHAND, LOIC · 2012 to 2014
$11.3M
Obesity, related comorbidities, and breast cancer outcomes in African AmericansR01CA185623 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI BANDERA, ELISA V, DEMISSIE, KITAW · 2014 to 2018
$6.2M
Gene Polymorphisms in Relation to Cancer in Black WomenR01CA098663 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI PALMER, JULIE R · 2003 to 2012
$5.3M
Race &Risk Factors for Early/Aggressive Breast CancerR01CA100598 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI AMBROSONE, CHRISTINE B. · 2004 to 2008
$4.8M
MULTIETHNIC/MINORITY COHORT STUDY OF DIET AND CANCERR01CA054281 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI KOLONEL, LAURENCE N. · 1993 to 2002
$4.5M
Uncoupling obesity from breast cancer in African American womenU01CA182898 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI DENIS, GERALD V, PALMER, JULIE R · 2013 to 2017
$3.1M
NCI NIH HHS K07 CA201334NCI NIH HHS P01 CA151135NCI NIH HHS P30 CA016086NCI NIH HHS P50 CA058223NCI NIH HHS R01 CA054281NCI NIH HHS R01 CA058420NCI NIH HHS R01 CA063464NCI NIH HHS R01 CA098663NCI NIH HHS R01 CA100598NCI NIH HHS R01 CA185623NCI NIH HHS U01 CA179715NCI NIH HHS U01 CA182898NCI NIH HHS UM1 CA164973NCI NIH HHS UM1 CA164974
6 · The paper itself

Abstract

The insulin/insulin-like growth factor (IGF) system and related pathways such as growth hormone, and leptin signaling have a key role in cancer development. It is unclear how germline variation in these pathways affects breast cancer risk. We conducted gene-based analyses of 184 genes in the insulin/IGF, growth hormone, and leptin pathways to identify genetic variation associated with risk of breast cancer overall, and for estrogen receptor (ER) subtypes. Tag single-nucleotide polymorphisms (SNPs) for each gene were selected and genotyped on a customized Illumina SNP array. Imputation was carried out using 1000 Genomes haplotypes. The analysis included 91,627 SNPs genotyped or imputed in 3,663 breast cancer cases, (1,983 ER-positive and 1,098 ER-negative) and 4,687 controls from the African American Breast Cancer Epidemiology and Risk consortium, a collaborative project of four large studies of breast cancer in African-American women (Carolina Breast Cancer Study, Black Women's Health Study, Women's Circle of Health Study, and Multiethnic Cohort). We used a multi-locus adaptive joint test to determine the association of each gene with overall breast cancer and ER subtypes. The most significant gene associations (

Identifiers

PMID27942580
PMCPMC5142758
OpenAlexW2533099547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.